Serrapeptase.
The inflammation enzyme. Dissolves dead tissue, reduces swelling. A protein-cutting enzyme grown from Serratia bacteria. Taken behind an acid-resistant coat so it gets past the stomach, it's used for swelling comfort and looser mucus.
Reviewed March 2026
- Category
- Enzyme
- Also filed under
- InflammationSwellingPain
What Serrapeptase is, and what it does.
- Does it work
- Suits people wanting enzyme support around post-strain swelling and mucus comfort, often alongside bromelain or papain. If you want help digesting meals, a digestive enzyme blend fits that job.
- How much to take
- Start with 120,000 to 240,000 activity units a day, away from food. Units describe the dose here, not milligrams, because the same weight can carry different activity.
- Time to feel it
- Days rather than hours. People tracking swelling or mucus comfort tend to describe a change across the first one to two weeks of daily use.
- The first dose
- Day one is quiet. The coating dissolves past the stomach and the enzyme starts working locally; what you'd notice builds over the following days.
- With regular use
- Weeks of daily use is how it's normally taken, with joint and soft tissue comfort described as a gradual easing rather than a step change.
- How well tolerated
- Usually well tolerated. Mild stomach upset and occasional skin reactions are reported. Check first if you take blood thinners or have surgery coming up.
- How it feels
- Undramatic. Most describe mucus that shifts more easily and tissue that feels less tight after a strain, noticed over days rather than felt per dose.
- The overlooked benefit
- The activity unit figure on the label is the real dose, not the milligram weight. Two products at identical milligrams can carry very different enzyme activity.
120,000 to 240,000 IU a day is where Serrapeptase works.
Source: Mazzone et al., Minerva Cardioangiol, 1990; Al-Khateeb & Nusair, Int J Surg, 2009
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 25 human trials with 60% consistency.
- swelling and soft tissue comfortRandomised trial
- mucus consistency and comfortable breathingRandomised trial
- everyday joint comfortNarrative review
- breakdown of fibrin and structural proteinsIn vitro study
Questions people ask about Serrapeptase.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Systemic proteolytic blends have paired serrapeptase with bromelain for decades because the two enzymes cut at different peptide bonds and stay active across different pH ranges. Both are taken away from food so they are absorbed rather than spent on the meal.
Papain is a cysteine protease with broad specificity, serrapeptase a metalloprotease with its own cleavage preference. Combining classes widens the range of peptide bonds a blend can act on.
Digestive enzyme blends are taken with a meal to act on food in the gut lumen, while serrapeptase is taken on an empty stomach so the enteric coating carries it past the stomach for absorption. Putting both in one dose defeats one of the two purposes.
Allicin-derived sulfur compounds reduce platelet aggregation, and serrapeptase acts on fibrin. Both nudge normal clotting in the same direction, so the combination is worth flagging around surgery or an existing blood-thinning regimen.
Long-chain omega-3s reduce platelet aggregability while serrapeptase acts on fibrin. The two effects on normal clotting add rather than cancel.
Ginkgolides antagonise platelet-activating factor. Layered on a fibrin-acting protease, the two shift normal clotting the same way.
Both enzymes hydrolyse peptide bonds and both are described in the literature as acting on fibrin in vitro. Combining them stacks the same class of activity, which matters for anyone already using something that affects platelet function or clotting. That additive direction is the reason to flag the pairing rather than a reason to recommend it.
Serrapeptase is a protein, so gastric pepsin at low pH digests it like any other dietary protein. Taking a supplemental pepsin or an uncoated serrapeptase into an acid stomach works against delivery of intact enzyme to the small intestine. This is the whole reason enteric coating exists for this ingredient.
Betaine hydrochloride is taken to lower gastric pH, and low pH is what denatures serrapeptase. An uncoated serrapeptase taken in the same dose window loses activity before it reaches the small intestine. Separating the two, or using a coated form, is the practical consequence.
Bicarbonate raises gastric pH, which reduces pepsin activity and the acid denaturation that inactivates an uncoated protease. The effect is transient and depends on dose and meal timing. It changes delivery conditions, not the enzyme itself.
Serrapeptase belongs to the serralysin family of zinc-dependent metalloproteases, so a zinc ion sits in the catalytic site and is required for bond cleavage. Chelating that zinc abolishes activity in vitro. This is enzyme chemistry and does not imply that oral zinc raises the activity of a swallowed dose.
Pancreatin supplies trypsin and chymotrypsin alongside amylase and lipase, so pairing it with a microbial protease adds protein-cleaving capacity in the same compartment. Formulators combine them for that reason. The added activity is measured in enzyme units, not milligrams, and the two products rarely declare units the same way.
Lipase acts on triglycerides while serrapeptase acts on peptide bonds, so the two cover different substrate classes with no overlap. Blended enzyme products pair them for coverage rather than for any interaction between the enzymes. Neither changes the other activity.
Amylase hydrolyses starch and does not compete for the protease substrate. The pairing broadens what a blend acts on. There is no chemical interaction between the two enzymes to report.
NAC lowers mucus viscosity by breaking disulphide crosslinks between mucin polymers, a different chemistry from cleaving peptide bonds. Products pair the two because both act on protein networks, though by unrelated routes. No trial has combined them.
Curcuminoids and this enzyme appear together in joint and recovery formulas. The pairing rests on formulation convention and separate mechanistic literature, not on a combination trial. Curcumin also carries its own platelet-related caution, which stacks with the protease caution rather than cancelling it.
MSM is a small sulphur-donating molecule with no proteolytic activity, so it neither helps nor hinders the enzyme chemically. It appears alongside serrapeptase in joint comfort blends. No combination data exists.
Quercetin is added to enzyme blends for its own described actions on mediator release. The two do not interact chemically in the capsule or the gut. Any combined effect is unmeasured.
Willow bark yields salicylate, which reduces platelet aggregation. Stacking it with an enzyme that is itself flagged for effects on fibrin and platelets pushes the same direction twice. Flag this pairing rather than build on it, particularly around surgery or dental work.
Ginger constituents reduce platelet aggregation in laboratory measures, and the effect is dose related. Combined with a fibrinolytic-type enzyme, the two act in the same direction. Worth naming so a formula does not stack three of these without noticing.
High-dose alpha-tocopherol reduces platelet aggregation and prolongs bleeding measures in reported human work. That direction adds to the protease caution rather than offsetting it. At ordinary dietary intakes the concern is small.
Grape seed proanthocyanidins are reported to reduce platelet aggregation in laboratory measures. Combining them with a fibrin-active enzyme stacks the same direction. This is a caution to note, not a benefit to claim.
Rutin has been formulated with proteolytic enzymes such as bromelain and trypsin for decades in European enzyme products. The rationale is the flavonoid contribution to capillary and vessel wall measures alongside the enzyme. The convention is old; the combination evidence for this specific enzyme is not.
Zinc carnosine is used for the gastric lining while an enteric-coated protease is designed to bypass the stomach entirely. The two occupy different compartments. The pairing is a formulation choice with no measured interaction.
Glutamine fuels the intestinal enterocyte and has no effect on protease activity. It is a common companion in gut formulas. No combination data for this enzyme exists.
Talk to a doctor before taking Serrapeptase if any of these apply to you: a blood thinner, empty stomach. These are flags to check first, not effects Serrapeptase is known to cause.
Not medical advice. Show the label to your pharmacist.What Serrapeptase actually does.
Serrapeptase is a serralysin-family zinc metalloendopeptidase originally isolated from Serratia species found in the silkworm gut. A zinc ion in the catalytic site is required for peptide bond cleavage, and removing that zinc abolishes activity in vitro.
The molecule is itself a protein, so gastric acid and pepsin denature and digest it. Oral products therefore rely on enteric coating or delayed-release encapsulation to carry intact enzyme past the stomach.
Enzyme content is expressed in activity units, most often serrapeptase units, measured against a defined protein substrate under standard conditions. Two products declaring the same milligram weight can carry different activity, which is why unit declarations and not milligrams describe the dose.
In cell-free assays the enzyme hydrolyses fibrin and other structural proteins. Activity in a test tube says nothing on its own about what reaches circulation after an oral dose, and the extent of intact absorption in humans is the open question in this literature.
Where Serrapeptase comes from.
Bacteria are grown in a tank and release the enzyme into the liquid around them. That liquid is filtered and cleaned up, the enzyme is measured by what it can do rather than what it weighs, and then it is usually given an acid-resistant coat so the stomach does not digest it first.
Built by fermentation, the same way vitamin B12 and many amino acids are made at scale. Controlled conditions, consistent output.
A defined broth carrying a sugar source, a nitrogen source such as soy peptone or yeast extract, and mineral salts including the zinc the enzyme needs in its active site.
A Serratia strain is grown in an aerated, pH-controlled vessel and secretes the protease into the medium. Yield depends on strain, aeration and induction conditions.
Biomass is separated from the broth by centrifugation and filtration; the enzyme stays in the clarified liquid because it is secreted rather than intracellular.
Ultrafiltration concentrates the protein, followed by precipitation or column steps to remove other broth proteins and endotoxin from the producing organism.
The concentrate is assayed against a protein substrate and cut with a carrier to a declared unit count per gram. Weight alone does not describe the dose.
Powder is dried gently to preserve folding, then either sold as bulk powder or built into an enteric-coated tablet or delayed-release bead.
Getting Serrapeptase from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In people followed after a fat-removal procedure, serrapeptase showed no detectable difference in tissue firmness or scar-tissue formation, and the authors described the evidence as limited.Cohort study. Bruno et al., 2026 (Aesthetic plastic surgery). PMID 41642311 ↗
These are the studies our verdict leans on, chosen from the 24 we read for Serrapeptase. The full linked list is below.
Problems people have reported.
Read this carefully. These are 1,318 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Serrapeptase is, not how risky it is. A report is not proof Serrapeptase caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.